Adrenomedullin 2/intermedin is a slow off-rate, long-acting endogenous agonist of the adrenomedullin2 G protein–coupled receptor
Open Access
- 4 May 2023
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (6) , 104785
Abstract
No abstract availableKeywords
Funding Information
- National Institute of General Medical Sciences (R01GM104251, R01GM130794)
- National Science Foundation (DMS1761320)
- National Institutes of Health
This publication has 69 references indexed in Scilit:
- The pharmacology of Adrenomedullin 2/IntermedinBritish Journal of Pharmacology, 2012
- Intermedin (adrenomedullin2) stabilizes the endothelial barrier and antagonizes thrombin‐induced barrier failure in endothelial cell monolayersBritish Journal of Pharmacology, 2011
- Features and development of CootActa Crystallographica Section D Structural Biology, 2010
- Intermedin is a new angiogenic growth factorAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Sustained cyclic AMP production by parathyroid hormone receptor endocytosisNature Chemical Biology, 2009
- Intermedin ameliorates vascular and renal injury by inhibition of oxidative stressAmerican Journal of Physiology-Renal Physiology, 2008
- Adrenomedullin signaling is necessary for murine lymphatic vascular developmentJournal of Clinical Investigation, 2008
- The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrityJournal of Clinical Investigation, 2008
- Use of a cAMP BRET Sensor to Characterize a Novel Regulation of cAMP by the Sphingosine 1-Phosphate/G13 PathwayJournal of Biological Chemistry, 2007
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996